Sinopharm Accord Reports Decline in Revenue and Profits for H1 2025
Sinopharm Group Co. Ltd. reported a decline in revenue and profits for its subsidiary, China National Accord Medicines Corporation Ltd. (Sinopharm Accord) for H1 2025. Revenue fell by 2.62% to 36.8 billion yuan, while net profit dropped by 10.43% to 665.9 million yuan. Operating cash flow decreased by 98.38%. However, total assets increased by 6.04% to over 50.4 billion yuan, and net assets attributable to shareholders rose by 2.64%.
Sinopharm Group Co. Ltd. has released its 2025 interim report highlighting the financial performance of its subsidiary, China National Accord Medicines Corporation Ltd. (“Sinopharm Accord”). The report details that for the six months ending 30 June 2025, Sinopharm Accord experienced a slight decrease in revenue, totaling 36.8 billion yuan, down 2.62% from the same period last year. The net profit attributable to shareholders of the listed company also saw a decline of 10.43%, amounting to 665.9 million yuan. Furthermore, net cash flow from operating activities dropped significantly by 98.38% compared to the previous year. Despite these decreases, Sinopharm Accord’s total assets saw an increase of 6.04%, reaching over 50.4 billion yuan, with net assets attributable to shareholders rising by 2.64%. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sinopharm Group Co. Ltd. published the original content used to generate this news brief on August 29, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
